ATE387451T1 - Chinazolinderivate als src- tyrosinkinaseinhibitoren - Google Patents

Chinazolinderivate als src- tyrosinkinaseinhibitoren

Info

Publication number: ATE387451T1
Authority: AT; Austria
Prior art keywords: tyrosine kinase; kinase inhibitors; quinazoline derivatives; src tyrosine; src
Prior art date: 2002-11-04

Application number

AT03769689T

Other languages

English (en)

Inventor

Patrick Ple

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-04

Filing date

2003-10-29

Publication date

2008-03-15

2003-10-29 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-03-15 Application granted granted Critical

2008-03-15 Publication of ATE387451T1 publication Critical patent/ATE387451T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT03769689T 2002-11-04 2003-10-29 Chinazolinderivate als src- tyrosinkinaseinhibitoren ATE387451T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02292736		2002-11-04
EP03290900		2003-04-10

Publications (1)

Publication Number	Publication Date
ATE387451T1 true ATE387451T1 (de)	2008-03-15

Family

ID=32313852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03769689T ATE387451T1 (de)	2002-11-04	2003-10-29	Chinazolinderivate als src- tyrosinkinaseinhibitoren

Country Status (27)

Country	Link
US (1)	US7462623B2 (de)
EP (1)	EP1562955B1 (de)
JP (2)	JP4593464B2 (de)
KR (1)	KR101089462B1 (de)
AR (1)	AR041884A1 (de)
AT (1)	ATE387451T1 (de)
AU (1)	AU2003278383B2 (de)
BR (1)	BR0315756A (de)
CA (1)	CA2503371C (de)
CO (1)	CO5560578A2 (de)
CY (1)	CY1108061T1 (de)
DE (1)	DE60319410T2 (de)
DK (1)	DK1562955T3 (de)
EG (1)	EG24957A (de)
ES (1)	ES2300619T3 (de)
IL (1)	IL168013A (de)
IS (1)	IS2568B (de)
MX (1)	MXPA05004858A (de)
MY (1)	MY137835A (de)
NO (1)	NO331951B1 (de)
NZ (1)	NZ539408A (de)
PL (1)	PL215161B1 (de)
PT (1)	PT1562955E (de)
RU (1)	RU2350618C2 (de)
SI (1)	SI1562955T1 (de)
TW (1)	TWI320786B (de)
WO (1)	WO2004041829A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7576074B2 (en)	2002-07-15	2009-08-18	Rice Kenneth D	Receptor-type kinase modulators and methods of use
ATE520403T1 (de)	2003-09-26	2011-09-15	Exelixis Inc	N-ä3-fluoro-4-(ä6-(methyloxy)-7-ä(3-morpholin-4 ylpropyl)oxyüquinolin-4-ylüoxy)phenylü-n'-(4- fluorophenyl)cyclopropane-1,1-dicarboxamid zur behandlung von krebs
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0427697D0 (en)	2004-12-17	2005-01-19	Astrazeneca Ab	Chemical process
WO2009068906A2 (en) *	2007-11-26	2009-06-04	Astrazeneca Ab	Combinations comprising zd4054 and a src family kinase inhibitor 172
TW201920110A (zh)	2009-01-16	2019-06-01	美商艾克塞里克斯公司	包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
DK2621481T4 (da)	2010-09-27	2023-01-09	Exelixis Inc	Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
TWI577671B (zh) *	2011-11-14	2017-04-11	Sunshine Lake Pharma Co Ltd	Aminoquinazoline derivatives and salts thereof and methods of use thereof
WO2017062500A2 (en)	2015-10-05	2017-04-13	The Trustees Of Columbia University In The City Of New York	Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
WO2017156350A1 (en)	2016-03-09	2017-09-14	K-Gen, Inc.	Methods of cancer treatment
EP3849534B1 (de)	2018-09-10	2025-03-05	Mirati Therapeutics, Inc.	Kombination von dasatinib und adagrasib zur behandlung von nicht-kleinzelligem lungenkarzinom

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2108120T3 (es) *	1991-05-10	1997-12-16	Rhone Poulenc Rorer Int	Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
PT100905A (pt) *	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
GB9205320D0 (en) *	1992-03-11	1992-04-22	Ici Plc	Anti-tumour compounds
GB9323290D0 (en)	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US6046206A (en) *	1995-06-07	2000-04-04	Cell Pathways, Inc.	Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) *	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
GB9624482D0 (en) *	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
US6184225B1 (en)	1996-02-13	2001-02-06	Zeneca Limited	Quinazoline derivatives as VEGF inhibitors
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
DE69709319T2 (de) *	1996-03-05	2002-08-14	Astrazeneca Ab, Soedertaelje	4-anilinochinazolin derivate
AU2103097A (en)	1996-03-15	1997-10-10	Zeneca Limited	Cinnoline derivatives and use as medicine
GB9707800D0 (en)	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
ATE227283T1 (de)	1996-07-13	2002-11-15	Glaxo Group Ltd	Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
NZ334125A (en) *	1996-09-25	2000-10-27	Zeneca Ltd	Quinoline derivatives inhibiting the effect of growth factors such as VEGF
EP1005470B1 (de)	1997-08-22	2007-08-01	AstraZeneca AB	Oxindolylchinazolinderivate als angiogenesehemmer
AU763669B2 (en)	1998-09-29	2003-07-31	Wyeth Holdings Corporation	Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
ES2241324T3 (es) *	1998-10-08	2005-10-16	Astrazeneca Ab	Derivados de quinazolina.
CZ303692B6 (cs)	1999-02-10	2013-03-13	Astrazeneca Ab	Chinazolinové deriváty jako inhibitory angiogeneze
WO2001021594A1 (en)	1999-09-21	2001-03-29	Astrazeneca Ab	Quinazoline compounds and pharmaceutical compositions containing them
GB9922171D0 (en)	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
UA72946C2 (uk) *	1999-11-05	2005-05-16	Астразенека Аб	Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
EP1272185B1 (de)	2000-03-06	2005-07-27	AstraZeneca AB	Verwendung von quinazolinderivate als inhibitoren der angiogenese
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
US7160889B2 (en) *	2000-04-07	2007-01-09	Astrazeneca Ab	Quinazoline compounds
UA73993C2 (uk) *	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0113057A (pt) *	2000-08-09	2003-07-08	Astrazeneca Ab	Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para produzir um efeito antiangiogênico e/ou efeito de redução da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento
AU7993801A (en)	2000-08-09	2002-02-18	Astrazeneca Ab	Chemical compounds
US7371765B2 (en)	2000-08-09	2008-05-13	Astrazeneca Ab	Quinoline derivatives having VEGF inhibiting activity
PL202812B1 (pl) *	2000-08-21	2009-07-31	Astrazeneca Ab	Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie
EP1326860A1 (de)	2000-10-13	2003-07-16	AstraZeneca AB	Quinazolin derivaten
EP1326859A1 (de) *	2000-10-13	2003-07-16	AstraZeneca AB	Chinazoline derivate mit aktivität gegen tumore
WO2002034744A1 (en)	2000-10-25	2002-05-02	Astrazeneca Ab	Quinazoline derivatives
US7141577B2 (en) *	2001-04-19	2006-11-28	Astrazeneca Ab	Quinazoline derivatives
WO2002092577A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
WO2002092579A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	4-anilinoquinazoline derivatives
WO2002092578A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
JP4326328B2 (ja)	2001-07-16	2009-09-02	アストラゼネカアクチボラグ	キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用
GB0126879D0 (en)	2001-11-08	2002-01-02	Astrazeneca Ab	Combination therapy
AU2002365664A1 (en)	2001-12-05	2003-06-17	Astrazeneca Ab	Quinoline derivatives as antitumour agents
PL371486A1 (en)	2002-02-01	2005-06-13	Astrazeneca Ab	Quinazoline compounds
GB0215823D0 (en)	2002-07-09	2002-08-14	Astrazeneca Ab	Quinazoline derivatives
DE60327323D1 (de)	2002-07-09	2009-06-04	Astrazeneca Ab	Chinazoline derivative und ihre anwendung in der krebsbehandlung
MXPA05001458A (es)	2002-08-09	2005-06-06	Astrazeneca Ab	Combinacion de zd6474, un inhibidor del receptor del factor de crecimiento endotelial vascular, con radioterapia en tratamiento de cancer.
GB0218526D0 (en)	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
GB0223380D0 (en)	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
GB0226434D0 (en) *	2002-11-13	2002-12-18	Astrazeneca Ab	Combination product
CA2514227C (en)	2003-02-13	2011-08-09	Astrazeneca Ab	Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent

2003
- 2003-10-29 CA CA2503371A patent/CA2503371C/en not_active Expired - Fee Related
- 2003-10-29 PT PT03769689T patent/PT1562955E/pt unknown
- 2003-10-29 PL PL376255A patent/PL215161B1/pl unknown
- 2003-10-29 AT AT03769689T patent/ATE387451T1/de active
- 2003-10-29 KR KR1020057007855A patent/KR101089462B1/ko not_active Expired - Fee Related
- 2003-10-29 BR BR0315756-3A patent/BR0315756A/pt not_active IP Right Cessation
- 2003-10-29 US US10/533,931 patent/US7462623B2/en not_active Expired - Fee Related
- 2003-10-29 WO PCT/GB2003/004703 patent/WO2004041829A1/en active IP Right Grant
- 2003-10-29 MX MXPA05004858A patent/MXPA05004858A/es active IP Right Grant
- 2003-10-29 RU RU2005117337/04A patent/RU2350618C2/ru not_active IP Right Cessation
- 2003-10-29 JP JP2005502127A patent/JP4593464B2/ja not_active Expired - Fee Related
- 2003-10-29 NZ NZ539408A patent/NZ539408A/en not_active IP Right Cessation
- 2003-10-29 SI SI200331192T patent/SI1562955T1/sl unknown
- 2003-10-29 DE DE60319410T patent/DE60319410T2/de not_active Expired - Lifetime
- 2003-10-29 EP EP03769689A patent/EP1562955B1/de not_active Expired - Lifetime
- 2003-10-29 ES ES03769689T patent/ES2300619T3/es not_active Expired - Lifetime
- 2003-10-29 DK DK03769689T patent/DK1562955T3/da active
- 2003-10-29 AU AU2003278383A patent/AU2003278383B2/en not_active Ceased
- 2003-10-30 TW TW092130284A patent/TWI320786B/zh not_active IP Right Cessation
- 2003-11-03 MY MYPI20034197A patent/MY137835A/en unknown
- 2003-11-04 AR ARP030104036A patent/AR041884A1/es not_active Application Discontinuation
2005
- 2005-04-13 IL IL168013A patent/IL168013A/en not_active IP Right Cessation
- 2005-04-19 NO NO20051900A patent/NO331951B1/no not_active IP Right Cessation
- 2005-04-30 EG EGNA2005000178 patent/EG24957A/xx active
- 2005-05-03 CO CO05042313A patent/CO5560578A2/es not_active Application Discontinuation
- 2005-05-19 IS IS7849A patent/IS2568B/is unknown
2008
- 2008-04-24 CY CY20081100460T patent/CY1108061T1/el unknown
2010
- 2010-07-26 JP JP2010167576A patent/JP2010270143A/ja active Pending

Also Published As

Publication number	Publication date
PT1562955E (pt)	2008-05-05
SI1562955T1 (sl)	2008-06-30
MXPA05004858A (es)	2005-07-22
AR041884A1 (es)	2005-06-01
MY137835A (en)	2009-03-31
NO331951B1 (no)	2012-05-14
CY1108061T1 (el)	2014-02-12
EP1562955B1 (de)	2008-02-27
TW200420567A (en)	2004-10-16
BR0315756A (pt)	2005-09-06
IS2568B (is)	2010-01-15
NZ539408A (en)	2007-09-28
JP4593464B2 (ja)	2010-12-08
TWI320786B (en)	2010-02-21
IL168013A (en)	2013-03-24
CA2503371C (en)	2011-01-11
JP2006506463A (ja)	2006-02-23
JP2010270143A (ja)	2010-12-02
AU2003278383A1 (en)	2004-06-07
WO2004041829A1 (en)	2004-05-21
RU2005117337A (ru)	2006-01-20
EP1562955A1 (de)	2005-08-17
RU2350618C2 (ru)	2009-03-27
DE60319410D1 (en)	2008-04-10
US7462623B2 (en)	2008-12-09
DK1562955T3 (da)	2008-06-02
PL376255A1 (en)	2005-12-27
PL215161B1 (pl)	2013-10-31
US20060122199A1 (en)	2006-06-08
NO20051900L (no)	2005-06-01
IS7849A (is)	2005-05-19
KR20050074526A (ko)	2005-07-18
CA2503371A1 (en)	2004-05-21
EG24957A (en)	2011-02-28
KR101089462B1 (ko)	2011-12-07
DE60319410T2 (de)	2009-02-19
AU2003278383B2 (en)	2007-06-14
HK1079195A1 (en)	2006-03-31
ES2300619T3 (es)	2008-06-16
CO5560578A2 (es)	2005-09-30

Publication	Publication Date	Title
ATE395346T1 (de)	2008-05-15	Chinazolinderivate als tyrosinkinaseinhibitoren
ATE446093T1 (de)	2009-11-15	Substituierte chinazolin-derivate als aurora- kinase inhibitoren
IL174258A0 (en)	2006-08-01	Quinazoline derivatives as tyrosine kinase inhibitors
ATE309996T1 (de)	2005-12-15	Chinolinonderivate als tyrosin-kinase inhibitoren
ATE452891T1 (de)	2010-01-15	Pyrimidopyrimidone als kinaseinhibitoren
ATE404564T1 (de)	2008-08-15	Diazepinoindolderivate als kinaseinhibitoren
IS6968A (is)	2003-09-26	Nýir týrósínkínasa tálmar
IL173200A0 (en)	2006-06-11	Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
ATE520671T1 (de)	2011-09-15	Pyrimidin-harnstoff-derivate als kinase-hemmer
DE60208661D1 (de)	2006-04-06	Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
ATE498613T1 (de)	2011-03-15	Chinazolinonderivate als parp-hemmer
ATE445613T1 (de)	2009-10-15	Indolylmaleimidderivative als proteinkinase-c- inhibitoren
DE60328735D1 (de)	2009-09-17	Chinazolinderivate
DE60313872D1 (de)	2007-06-28	Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DK1534290T3 (da)	2012-04-10	Hidtil ukendte kinasehæmmere
DE602004025258D1 (de)	2010-03-11	Aminotriazol-verbindungen als proteinkinase-hemmer
DE602004004553D1 (de)	2007-03-15	Chinazolinderivate
ATE450528T1 (de)	2009-12-15	Chinazolinderivate als antitumormittel
AU2003233455A1 (en)	2003-10-13	Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors
ATE393159T1 (de)	2008-05-15	Heterobicyclische pyrazolderivate als kinaseinhibitoren
IL173483A0 (en)	2006-06-11	Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases
DE602004026905D1 (de)	2010-06-10	2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
ATE521603T1 (de)	2011-09-15	Chinazolinderivate als tyrosinkinaseinhibitoren
ATE468338T1 (de)	2010-06-15	Pyrrolochinolinderivate und ihre verwendung als proteinkinasehemmer
DE60322544D1 (de)	2008-09-11	Glycinamid-derivate als raf-kinase-hemmer

Legal Events

Date	Code	Title	Description
2008-09-15	UEP	Publication of translation of european patent specification	Ref document number: 1562955 Country of ref document: EP

Date

Code

Title

Description

2008-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1562955

Country of ref document: EP